Search

Your search keyword '"Phan, Thang Thanh"' showing total 24 results
Start Over Author "Phan, Thang Thanh"
24 results on '"Phan, Thang Thanh"'

1. The diagnostic performance of AFP and PIVKA-II models for non-B non-C hepatocellular carcinoma

Author

Tran, Vinh Thanh, Phan, Thang Thanh, Nguyen, Tran Bao, Le, Thao Thi, Tran, Thanh-Tram Thi, Nguyen, Anh-Thu Thi, Nguyen, Hang Thuy, Nguyen, Ngoc-Diep Bui, Ho, Toan Trong, Pho, Suong Phuoc, Nguyen, Thuy-An Thi, Nguyen, Hue Thi, Mai, Huyen Thi, Pham, Bich-Tuyen Thi, Nguyen, Khoa Dinh, Le, Binh Thanh, Nguyen, Thuc Tri, and Nguyen, Son Truong more...

Published
2023
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results

6. Incidence of SARS-CoV-2 Infection during the Omicron Variant Emergence in Southern Vietnam: Prior Infection versus Third-Dose Vaccination

Author

Phan, Thang Thanh, primary, Nguyen, Tran Bao, additional, Phung, Quynh-Giao Thi, additional, Tran, Vinh Thanh, additional, Ho, Toan Trong, additional, Pho, Suong Phuoc, additional, Quach, Trung Hien, additional, Truong, An Thuy, additional, Nguyen, Hang Thuy, additional, Nguyen, Thuc Tri, additional, and Nguyen, Son Truong, additional more...

Published
2022
Full Text
View/download PDF

9. The diagnostic power of CD117, CD13, CD56, CD64, and MPO in rapid screening acute promyelocytic leukemia

Author

Tran, Vinh Thanh, primary, Phan, Thang Thanh, additional, Mac, Hong-Phuoc, additional, Tran, Tung Thanh, additional, Ho, Toan Trong, additional, Pho, Suong Phuoc, additional, Nguyen, Van-Anh Ngoc, additional, Vo, Truc-My, additional, Nguyen, Hue Thi, additional, Le, Thao Thi, additional, Vo, Tin Huu, additional, and Nguyen, Son Truong, additional more...

Published
2020
Full Text
View/download PDF

11. Additional file 4 of The diagnostic power of CD117, CD13, CD56, CD64, and MPO in rapid screening acute promyelocytic leukemia

Author

Tran, Vinh Thanh, Phan, Thang Thanh, Hong-Phuoc Mac, Tran, Tung Thanh, Ho, Toan Trong, Suong Phuoc Pho, Van-Anh Ngoc Nguyen, Truc-My Vo, Nguyen, Hue Thi, Le, Thao Thi, Vo, Tin Huu, and Nguyen, Son Truong more...

Subjects
Software_PROGRAMMINGLANGUAGES
Abstract

Additional file 4: Figure S3. Molecular and cytogenetic results of a case with APL (A) and a non-APL (B).

Published
2020
Full Text
View/download PDF

12. Additional file 5 of The diagnostic power of CD117, CD13, CD56, CD64, and MPO in rapid screening acute promyelocytic leukemia

Author

Tran, Vinh Thanh, Phan, Thang Thanh, Hong-Phuoc Mac, Tran, Tung Thanh, Ho, Toan Trong, Suong Phuoc Pho, Van-Anh Ngoc Nguyen, Truc-My Vo, Nguyen, Hue Thi, Le, Thao Thi, Vo, Tin Huu, and Nguyen, Son Truong more...

Abstract

Additional file 5: Table S2. Antigen expression according to the cut-off value of 20% events.

Published
2020
Full Text
View/download PDF

13. Additional file 2 of Smoking habit and chemo-radiotherapy and/or surgery affect the sensitivity of EGFR plasma test in non-small cell lung cancer

Author

Tran, Vinh Thanh, Phan, Thang Thanh, Nguyen, Son Truong, Bich-Thu Tran, Ho, Toan Trong, Suong Phuoc Pho, Nguyen, Tran Bao, Pham, Tuyen Thi Bich, Le, Anh Tuan, Le, Vu Thuong, and Nguyen, Hang Thuy

Abstract

Additional file 2: Table S2.EGFR mutation status between groups of patient’s characteristics.

Published
2020
Full Text
View/download PDF

16. Additional file 6 of The diagnostic power of CD117, CD13, CD56, CD64, and MPO in rapid screening acute promyelocytic leukemia

Author

Tran, Vinh Thanh, Phan, Thang Thanh, Hong-Phuoc Mac, Tran, Tung Thanh, Ho, Toan Trong, Suong Phuoc Pho, Van-Anh Ngoc Nguyen, Truc-My Vo, Nguyen, Hue Thi, Le, Thao Thi, Vo, Tin Huu, and Nguyen, Son Truong more...

Abstract

Additional file 6: Figure S4. BMA analysis identified the five-factors optimal model for APL.

Published
2020
Full Text
View/download PDF

17. Additional file 3 of The diagnostic power of CD117, CD13, CD56, CD64, and MPO in rapid screening acute promyelocytic leukemia

Author

Tran, Vinh Thanh, Phan, Thang Thanh, Hong-Phuoc Mac, Tran, Tung Thanh, Ho, Toan Trong, Suong Phuoc Pho, Van-Anh Ngoc Nguyen, Truc-My Vo, Nguyen, Hue Thi, Le, Thao Thi, Vo, Tin Huu, and Nguyen, Son Truong more...

Subjects
Software_PROGRAMMINGLANGUAGES
Abstract

Additional file 3: Figure S2. Flow cytometric plots of a case with APL (A) and a non-APL (B).

Published
2020
Full Text
View/download PDF

19. Emergence role of nucleated red blood cells in molecular response evaluation for chronic myeloid leukemia

Author

Phan,Thang Thanh, Vy,Ha The, Ho,Toan Trong, Tran,Vinh Thanh, Tran,Tung Thanh, Pho,Suong Phuoc, Pham,Tuyen Thi Bich, Le,Thao Thi, and Nguyen,Son Truong

Subjects
hemic and lymphatic diseases, International Journal of General Medicine
Abstract

Thang Thanh Phan1,2, Ha The Vy3, Toan Trong Ho2, Vinh Thanh Tran2, Tung Thanh Tran3, Suong Phuoc Pho1, Tuyen Thi Bich Pham2, Thao Thi Le2, Son Truong Nguyen4,5 1Biomolecular & Genetic Unit, Clinical Cancer Center, Cho Ray Hospital, Ho Chi Minh City 700000, Vietnam; 2Laboratory D Unit, Clinical Cancer Center, Cho Ray Hospital, Ho Chi Minh City 700000, Vietnam; 3Department of Hematology, Cho Ray Hospital, Ho Chi Minh City 700000, Vietnam; 4Department of General Director, Cho Ray Hospital, Ho Chi Minh City 700000, Vietnam; 5Department of the Vice Minister, Ministry of Health, Hanoi City 100000, VietnamCorrespondence: Son Truong NguyenDepartment of the Vice Minister, Ministry of Health, 138A Giang Vo Street, Ba Dinh District, Hanoi City 100000, VietnamTel +84 246 273 2273Fax +84 243 846 4051Email truongson_cr@yahoo.com.vnPurpose: To investigate and evaluate the role of nucleated red blood cells (NRBCs) and other markers in predicting remission failure in chronic myeloid leukemia (CML) patients treated with imatinib.Methods: Seventy-one CML patients with BCR-ABL(+) in bone marrow cells were selected for this study. Molecular response evaluations were done every three months according to the recommendations of European LeukemiaNet (ELN). Patients were defined as remission failure if BCR-ABL transcripts >10% after 6months (T6), >1% after 12months (T12), and >0.1% after 18 (T18) months of treatment. The logistic regression was used to determine the optimal cut-off point of each marker and test the association of marker level with remission failure.Results: The median NRBC, white blood cells, blast cells, basophils, and platelets were declined parallel with the decreases of BCR-ABL transcripts in bone marrow cells after 6months of treatment (P more...

Published
2019

21. The prognostic impact of neutrophil to lymphocyte ratio in advanced non-small-cell lung cancer patients treated with EGFR TKI

Author

Phan,Thang Thanh, Ho,Toan Trong, Nguyen,Hu Thi, Nguyen,HT, Tran,Thu B, Nguyen,Son Truong, Phan,Thang Thanh, Ho,Toan Trong, Nguyen,Hu Thi, Nguyen,HT, Tran,Thu B, and Nguyen,Son Truong

Abstract

Thang Thanh Phan,1 Toan Trong Ho,1 Hue Thi Nguyen,1 Hang Thuy Nguyen,2 Thu Bich Tran,3 Son Truong Nguyen1 1Laboratory D Unit, Clinical Cancer Center, Cho Ray Hospital, Ho Chi Minh City, Vietnam; 2Pathology Department, Cho Ray Hospital, Ho Chi Minh City, Vietnam; 3Faculty of Biology and Biotechnology, University of Science, VNU-HCM, Ho Chi Minh City, Vietnam Purpose: To identify and clarify the roles of inflammatory markers in prognosis for advanced non-small cell lung cancer (NSCLC) patients treated with EGFR tyrosine kinase inhibitor (TKI). Patients and methods: One hundred and twelve adenocarcinoma, clinical stage IV, NSCLC patients with either EGFR exon 19 deletion (E19del) or EGFR exon 21  L858R substitution mutation (L858R) were selected for this study. The blood cell count at different stages of treatment was used to calculate the inflammatory markers. The Kaplan–Meier statistics and Cox regression model were used to test the differences of progression-free survival (PFS) between groups by the optimal cutoff point of biomarkers. Results: The median values of white blood cell (WBC), neutrophil to lymphocyte ratio (NLR), monocyte to lymphocyte ratio (MLR) and platelet to lymphocyte ratio (PLR) in NSCLC patients tended to be reduced after 3 months treated with EGFR TKI and increased conversely when the disease develops progression (P<0.001). With an optimal cutoff point of 2.96, NLR is the best prognostic marker in prediction of clinical response among the investigated markers (area under the curve [AUC]=0.873, 95% CI: 0.821–0.926, P<0.001), and it is an independent predictive marker (OR=3.52, 95% CI: 1.42–8.71, P<0.001). With optimal cutoff point of 0.38, MLR is also a predictive marker in response evaluation (AUC=0.762, 95% CI: 0.691–0.832). Univariate analyses have shown that the larger tumor size (>3cm) and the high level of pretreatment NLR were associated with the shortening of PFS more...

Published
2018